Oncotarget

Research Papers:

Novel roles of TMEM100: inhibition metastasis and proliferation of hepatocellular carcinoma

Dipeng Ou _, Hao Yang, Dong Hua, Shuai Xiao and Lianyue Yang

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:17379-17390. https://doi.org/10.18632/oncotarget.3954

Metrics: PDF 1934 views  |   HTML 1789 views  |   ?  


Abstract

Dipeng Ou1,*, Hao Yang1,*, Dong Hua1, Shuai Xiao1 and Lianyue Yang2,3

1 Department of Geratic Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China

2 Department of Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China

3 Liver Cancer Laboratory, Xiangya Hospital, Central South University, Changsha, Hunan, China

* These authors have contributed equally to this work

Correspondence to:

Dipeng Ou, email:

Keywords: TMEM100; HCC; metastasis; proliferation; prognosis

Received: January 10, 2015 Accepted: April 08, 2015 Published: April 29, 2015

Abstract

Transmembrane protein 100 (TMEM100) was activated by ALK1/TGF-β signaling. We found that TMEM100 was decreased in hepatocellular carcinoma (HCC) tissues and in highly metastatic cell lines. Overexpressed of TMEM100 inhibited invasion, migration and proliferation. Low levels of TMEM100 were associated with cirrhosis, tumor size, Tumor nodule number, TNM stage, BCLC stage, Edmondson-Steiner Stage and vein invasion. Furthermore, TMEM100 was an independent risk factor for overall survival (P = 0.03) and disease-free survival (P = 0.019). The current findings suggest that TMEM100 functions as a tumor suppressor in HCC metastasis and proliferation.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 3954